Extra indication for VivaGel
Wednesday, 09 July, 2008
Melbourne biotech Starpharma [ASX: SPL] has announced plans to adapt the development of its vaginal microbicide VivaGel to incorporate the treatment of bacterial vaginosis.
VivaGel is currently in clinical trials as a prevention against the viruses such as HIV, genital herpes (HSV) and genital warts (HPV), and as a potential contraceptive. This is the first indication for which VivaGel might be used as a treatment.
Early tests suggest that VivaGel is able to reverse the imbalance between vaginal lactobacilli and disease-causing bacteria which is a characteristic of the condition.
Bacterial vaginosis is a major cause of vaginal infection, is implicated in pelvic inflammatory disease and may be associated with an increased risk of STIs and abortion.
Starpharma CEO Dr Jackie Fairley said the application was of interest because of its potential to open up new and rapid paths to market for VivaGel.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
